Grade B evidence also suggested that exercise may improve prostate cancer patients ' muscle mass , muscular strength , functional performance ( walking and sit to st and speed ) , as well as health-related , social and physical quality of life .
These effects appeared greater for group-rather than home-based-exercise , especially if these programs included resistance training .
CONTEXT Prostate cancer patients , especially those on and rogen deprivation therapy ( ADT ) , experience many symptoms that make it difficult to maintain their independence and quality of life .
Because ADT acts by means of reducing testosterone production , exercise may offset many of the ADT side effects and those of the cancer itself .
OBJECTIVES This systematic review of the literature evaluates whether exercise could reduce symptoms and improve quality of life for prostate cancer patients .
The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer
Objective . To evaluate body composition changes , specifically skeletal muscle mass , in men receiving and rogen deprivation with luteinizing-hormone releasing hormone-agonist ( LHRH-A ) for prostate cancer ( PCa ) in comparison with healthy controls . Design . Retrospective analysis of body composition changes in men with prostate cancer receiving LHRH-A therapy from 2 clinical trials compared to men without prostate cancer serving as a placebo-control in another clinical trial . Setting . Clinical Research Center in Connecticut . Participants . Thirty men ( > 60 years ) receiving 6 months of LHRH-A therapy for PCa were compared to a healthy group of 25 men without PCa . Measurements . Appendicular skeletal muscle/height2 ( ASM/ht2 ) , lean and fat mass were assessed by dual energy x-ray absorptiometry . Total testosterone levels were assessed by enzyme immunoassay . Results . At baseline , 12/30 ( 40 % ) of the treatment group and 7/25 ( 28 % ) of the control group ( p = 0.11 ) met criteria for sarcopenia . There were no differences between control groups in ASM/ht2 or lean mass . The LHRH-A group had a higher percent body fat than the control group , 29.8 ± 6.3 versus 26.3 ± 4.6 ( p = 0.02 ) . ASM/ht2 and lean mass decreased in the LHRH-A group from 7.5 ± 0.9 kg to 7.3 ± 0.9 kg ( −2.3 % ± 0.03 ; p ⩽ 0.001 ) and 53.5 ± 5.4 kg to 52.3 ± 5.3 kg ( −2.1 % ± 0.03 ; p ⩽ 0.001 ) , respectively . There was no muscle loss in the control group . At 6 months , the LHRH-A group had increased percent body fat from 29.8 ± 6.4 to 32.2 ± 5.8 ( 9.5 % ± 0.13 ; p ⩽ 0.001 ) , whereas the control group had decreased in percent body fat from 26.6 ± 4.6 to 25.3 ± 5.0 ( −3.8 % ± 0.08 ; p = 0.02 ) . Conclusions . Men  undergoing LHRH-A treatment for PCa decreased appendicular skeletal muscle and lean tissue and increased body fat within 6 months of initiation of therapy . Lifestyle changes or medical interventions to minimize the effects of and rogen deprivation therapy for PCa deserve investigation
Grade B evidence also suggested that exercise may improve prostate cancer patients ' muscle mass , muscular strength , functional performance ( walking and sit to st and speed ) , as well as health-related , social and physical quality of life .
These effects appeared greater for group-rather than home-based-exercise , especially if these programs included resistance training .
CONTEXT Prostate cancer patients , especially those on and rogen deprivation therapy ( ADT ) , experience many symptoms that make it difficult to maintain their independence and quality of life .
Because ADT acts by means of reducing testosterone production , exercise may offset many of the ADT side effects and those of the cancer itself .
OBJECTIVES This systematic review of the literature evaluates whether exercise could reduce symptoms and improve quality of life for prostate cancer patients .